Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines

TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule